GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Price-to-Owner-Earnings

AZN (AstraZeneca) Price-to-Owner-Earnings : 23.25 (As of Oct. 31, 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Price-to-Owner-Earnings?

As of today (2024-10-31), AstraZeneca's share price is $71.15. AstraZeneca's Owner Earnings per Share (TTM) ended in Jun. 2024 was $3.06. It's Price-to-Owner-Earnings for today is 23.25.


The historical rank and industry rank for AstraZeneca's Price-to-Owner-Earnings or its related term are showing as below:

AZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.38   Med: 25.32   Max: 50.23
Current: 23.28

During the past 13 years, the highest Price-to-Owner-Earnings of AstraZeneca was 50.23. The lowest was 14.38. And the median was 25.32.


AZN's Price-to-Owner-Earnings is ranked better than
52.35% of 426 companies
in the Drug Manufacturers industry
Industry Median: 26.755 vs AZN: 23.28

As of today (2024-10-31), AstraZeneca's share price is $71.15. AstraZeneca's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $2.07. Therefore, AstraZeneca's PE Ratio (TTM) for today is 34.37.

As of today (2024-10-31), AstraZeneca's share price is $71.15. AstraZeneca's EPS without NRI for the trailing twelve months (TTM) ended in was $2.26. Therefore, AstraZeneca's PE Ratio without NRI for today is 31.50.

During the past 13 years, AstraZeneca's highest PE Ratio without NRI was 534.95. The lowest was 18.21. And the median was 38.32.


AstraZeneca Price-to-Owner-Earnings Historical Data

The historical data trend for AstraZeneca's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Price-to-Owner-Earnings Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.36 26.73 41.02 19.94 22.91

AstraZeneca Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.39 22.13 22.91 25.37 26.26

Competitive Comparison of AstraZeneca's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, AstraZeneca's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Price-to-Owner-Earnings falls into.



AstraZeneca Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

AstraZeneca's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=71.15/3.06
=23.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AstraZeneca  (NAS:AZN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


AstraZeneca Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca Headlines

From GuruFocus